ArticleScientific reports2025
Polyethylene glycol precipitation is a useful method for excluding the interference of unexplained elevated CA 19-9.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
With improved living standards and increased health awareness among Chinese residents, carbohydrate antigen 19-9 (CA 19-9) has become a routine marker in health examinations. Elevated CA 19-9 levels are frequently observed in clinical practice. Although chemiluminescence technology is widely recognized for its high sensitivity and specificity, it cannot eliminate interference, which may lead to deviations and misdiagnoses. This study aims to find a simple and effective method to confirm and exclude the interference of CA 19-9 on the Abbott platform. 342 individuals with unexplained elevated CA 19-9 in serial determinations for more than 6 months were included as cases. Serum samples from individuals with persistently elevated CA 19 -9 levels were evaluated via sialidase treatment, polyethylene glycol (PEG) precipitation, gel filtration chromatography (GFC), gradient dilution assays, heterophile antibody blocking assays and rheumatoid factor titer assays. Out of 342 individuals with elevated CA 19-9, 77 cases were confirmed as interferent by the sialidase treatment. There was a significant consistency between the PEG precipitation and sialidase treatment results (kappa = 0.920). Compared with the sialidase treatment method, the specificity of the PEG precipitation method was 96.2%, and the sensitivity was 100%. When the cutoff value for the CA 19-9 recovery after PEG precipitation was below 37.9%, the area under the curve (AUC) was highest at 0.993 (95% CI 98.5-99.8%). The PEG precipitation method is useful and reliable for patients with unexplained elevated CA 19-9. This method could effectively identify the interference, reduce clinical misdiagnosis, alleviate unnecessary financial burdens on patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.